GeoVax Discontinues COVID-19 Vaccine Program; Raises $3.5M via Warrants & PIPE

GeoVax Labs, Inc. filed an S-1 registration statement for the resale of 7,639,967 shares of common stock by selling stockholders, following recent financing activities. The company announced a strategic reprioritization, discontinuing its GEO-CM04S1 COVID-19 vaccine candidate to focus resources on its lead programs, GEO-MVA and Gedeptin®. This decision was driven by the evolving COVID-19 vaccine market and a focus on programs with clearer regulatory pathways. GeoVax recently raised approximately $844,080 from a warrant exercise inducement and $2.7 million from a private placement of pre-funded and common warrants. The company continues to face operating losses and has received a "going concern" opinion from its auditors, with existing cash sufficient only into June 2026.